Showing results (51-60 of 100) with videos related to
Sort By:
Pageof 10
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 12, 2015
Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer AgentsGeorge Dranitsaris, Roger B Cohen, Gary Acton, et al.European Journal of Immunology|July 9, 2011
The central role of CD30L/CD30 interactions in allergic rhinitis pathogenesis in miceTakafumi Fuchiwaki, Xun Sun, Kenjiro Fujimura, et al.Emergency Medicine Clinics of North America|October 12, 2004
Aortic disastersRobert L Rogers, Ryan McCormackThe Journal of Rheumatology|April 3, 2003
Systemic and local expression of perforin in lymphocyte subsets in acute and chronic rheumatoid arthritisGordan Gulan, Jagoda Ravlic-Gulan, Natasa Strbo, et al.Frontiers in Immunology|March 18, 2020
Impaired B Cell Function in Mice Lacking Perforin-2Daniela Frasca, Alain Diaz, Maria Romero, et al.Immunologic Research|November 26, 2013
The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve successRobert G Newman, Duncan B Ross, Henry Barreras, et al.Journal of Hepatology|September 10, 2002
Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infectionGabriella Pár, Daniel Rukavina, Eckhard R Podack, et al.American Journal of Reproductive Immunology (New York, N.Y. : 1989)|January 9, 2003
IL-18 is present at the maternal-fetal interface and enhances cytotoxic activity of decidual lymphocytesVlatka S Tokmadzić, Yoshiyuki Tsuji, Tatjana Bogović, et al.Cancer Gene Therapy|November 8, 2003
Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinomaLuis E Raez, Peter A Cassileth, James J Schlesselman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2004
Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancerLuis E Raez, Peter A Cassileth, James J Schlesselman, et al.Pageof 10